Tofacitinib for the treatment of ulcerative colitis: analysis of malignancy rates from the OCTAVE clinical programme

被引：0

作者：

Lichtenstein, G. R. ^{[1
]}

Ciorba, M. A. ^{[2
]}

Rogler, G. ^{[3
]}

Quirk, D. ^{[4
]}

Nduaka, C. I. ^{[4
]}

Pedersen, R. D. ^{[4
]}

Lawendy, N. ^{[4
]}

Chan, G. ^{[4
]}

Su, C. ^{[4
]}

Panes, J. ^{[5
]}

机构：

[1] Univ Penn, Perelman Sch Med, Div Gastroenterol, Philadelphia, PA 19104 USA

[2] Washington Univ, Div Gastroenterol, St Louis, MO USA

[3] Univ Zurich, Dept Gastroenterol & Hepatol, Zurich, Switzerland

[4] Pfizer Inc, Collegeville, PA USA

[5] Hosp Clin Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain

来源：

JOURNAL OF CROHNS & COLITIS | 2018年 / 12卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

DOP025

引用

页码：S48 / S49

页数：2

共 3 条

[1] Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials [J].

Cohen, Stanley B. ;

Tanaka, Yoshiya ;

Mariette, Xavier ;

Curtis, Jeffrey R. ;

Lee, Eun Bong ;

Nash, Peter ;

Winthrop, Kevin L. ;

Charles-Schoeman, Christina ;

Thirunavukkarasu, Krishan ;

DeMasi, Ryan ;

Geier, Jamie ;

Kwok, Kenneth ;

Wang, Lisy ;

Riese, Richard ;

Wollenhaupt, Juergen .

ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (07) :1253-1262

[2]

Lichtenstein GR, 2017, AM J GASTROENTEROL, V112

[3] Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis [J].

Sandborn, William J. ;

Su, Chinyu ;

Sands, Bruce E. ;

D'Haens, Geert R. ;

Vermeire, Severine ;

Schreiber, Stefan ;

Danese, Silvio ;

Feagan, Brian G. ;

Reinisch, Walter ;

Niezychowski, Wojciech ;

Friedman, Gary ;

Lawendy, Nervin ;

Yu, Dahong ;

Woodworth, Deborah ;

Mukherjee, Arnab ;

Zhang, Haiying ;

Healey, Paul ;

Panes, Julian .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (18) :1723-1736

← 1 →